Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Date:6/8/2009

loodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO and WALTHAM, Mass., July 29, ... LLP is investigating whether certain officers ... breached their fiduciary duties to shareholders.  AMAG Pharmaceuticals ... on maternal health, anemia, and cancer supportive care.  ... to reduce the risk of preterm birth in ...
(Date:7/29/2015)... July 29, 2015  Cryoport, Inc. (NASDAQ: ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, announced today that the ... stock and warrants (the "Units") under a registered public ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015   KaloBios ... antibody company focused on developing innovative therapies to benefit ... focus on oncology, announced today that the U.S. Food ... new drug (IND) application for KB003, an anti-GM-CSF monoclonal ... and that the IND is now active. ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of AMAG Pharmaceuticals, Inc. (AMAG) on Behalf of Shareholders 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5
... , PRINCETON, N.J., Nov. 9 Pharmasset, Inc. (Nasdaq: ... Lazard Capital Markets Healthcare Conference. The conference will be held ... 17-19, 2009). , Schaefer Price, Pharmasset,s President and Chief Executive ... November 18, 2009 at 3:45 PM (ET). , To access ...
... 9 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... date and increased the purchase price of its previously ... is offering to purchase, for cash, up to $65,000,000 ... its outstanding 2.875% Senior Subordinated Convertible Notes due 2010. ...
Cached Medicine Technology:Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 2Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note 3
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... success of musical artists to crowd-funding campaigns that give small businesses financial support, ... health solutions company and innovator in employee health management programs, unveiled today a ...
(Date:7/29/2015)... ... July 29, 2015 , ... Gender minority people ... 2012, Massachusetts law has provided legal protections against discrimination on the basis of ... not protect against discrimination based on gender identity in places open to the ...
(Date:7/29/2015)... Washington, DC (PRWEB) , ... July 29, 2015 , ... ... a company rebrand, changing its name to Rock the Reformer ® by Potomac Pilates. ... website - http://www.RockTheReformer.com . Rock the Reformer ® by Potomac Pilates will continue ...
(Date:7/29/2015)... ... July 29, 2015 , ... More than 28,000 students ... of children living with autism will converge upon Penn State to share the ... The National Autism Conference will be held Aug. 3-6 at the Penn Stater ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the ... expiring November 30, 2019, during its recent meeting. , The Commission received renewal ... program’s compliance with the NCCA’s Standards for the Accreditation of Certification Programs. ...
Breaking Medicine News(10 mins):Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 2Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 3Health News:StayWell Unveils Employer Guide to Developing Effective Employee Wellness Champion Networks 4Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3
... , , BASKING RIDGE, N.J., Sept. ... the development of antithrombotic therapeutic aptamers with active control ... the first patient in a Phase 2b, randomized, partially-blinded, ... the REG1 anticoagulation system (REG1) was achieved. REG1 ...
... TARRYTOWN, N.Y., Sept. 9 Bayer Diabetes Care today ... glucose meters -- Pink and Purple. , , ... to use(1) features as the original silver BREEZE2 meter, such as ... so users do not have to handle individual strips every time ...
... to develop PAD if they had constellation of other ... News) -- Women with metabolic syndrome are at high ... dramatically raises the risk of heart disease and stroke. ... taking part in the Women,s Health Study, researchers identified ...
... ... Staffing and Scheduling Earned the Highest Score Based on Direct Product Evaluations and In-depth, ... ... 9, 2009 -- Today at the Nursing Management Congress2009, RES-Q® Healthcare Systems announced that ...
... , WALTHAM, Mass., Sept. 9 ... research and advisory firms focusing on pharmaceutical and healthcare issues, ... messages among the ten surveyed osteoporosis brands likely as a ... commonly recalled that Sally Field promoted the brand or that ...
... , , ATLANTA, ... may have ended, but financial incentives for improving health and appearance ... Surgical Associates, "Cash for Crow,s Feet" program offers a ... at half the typical cost, said Dr. David R. Fern, FACS. ...
Cached Medicine News:Health News:Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System 2Health News:Regado Biosciences Announces First Patient Enrolled in RADAR (Phase 2b) Study of REG1 Anticoagulation System 3Health News:Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time 2Health News:Metabolic Syndrome May Raise Risk of Peripheral Artery Disease 2Health News:RES-Q Labor Resource Management Ranked as the Top Staff Scheduling System Solution in KLAS 2009 Special Report 2Health News:Both Patients and Physicians Most Frequently Recall Roche's Boniva Messages and Link Them to the Sally Field Osteoporosis Campaign 2Health News:Both Patients and Physicians Most Frequently Recall Roche's Boniva Messages and Link Them to the Sally Field Osteoporosis Campaign 3Health News:'Cash For Crow's Feet' Program Offers Effective - and Affordable - Laser Skin Treatments 2
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
Developed for reconstructive plastic surgery with E-Type coupling. Order blades by size from 12 mm, 25 mm, 50 mm or 75 mm depending on your specific case requirements. Blades come in packs of 10....
Medicine Products: